BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen YS, Wang CC, de Villa VH, Wang SH, Cheng YF, Huang TL, Jawan B, Chiu KW, Chen CL. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant. 2002;16:405-409. [PMID: 12437618 DOI: 10.1034/j.1399-0012.2002.01133.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Lei JY, Yan LN. Intraoperative “no go” donor hepatectomy in living donor liver transplantation. Transplant Proc. 2013;45:2253-2257. [PMID: 23953536 DOI: 10.1016/j.transproceed.2013.02.119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
2 Prieto M. Antibody to hepatitis B core antigen-positive grafts: Not perfect but no longer marginal: Editorial. Liver Transpl 2009;15:1164-8. [DOI: 10.1002/lt.21814] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
3 Trotter JF. Selection of donors for living donor liver transplantation. Liver Transpl. 2003;9:S2-S7. [PMID: 14528421 DOI: 10.1053/jlts.2003.50221] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
4 Fabrizi F, Bunnapradist S, Lunghi G, Villa M, Martin P. Transplanting Solid Organs from HBsAg Negative Donors Positive for Antibody to Hepatitis B Core Antigen: The Implications. The International Journal of Artificial Organs 2018;26:972-83. [DOI: 10.1177/039139880302601102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Chotiyaputta W, Pelletier SJ, Fontana RJ, Lok AS. Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers. Hepatol Int 2010;4:707-15. [PMID: 21286341 DOI: 10.1007/s12072-010-9188-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
6 Liu C. Impact of right-lobe live donor liver transplantation on patients waiting for liver transplantation. Liver Transplantation 2003;9:863-9. [DOI: 10.1053/jlts.2003.50163] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 2.0] [Reference Citation Analysis]
7 Chang MS, Olsen SK, Pichardo EM, Stiles JB, Rosenthal-Cogan L, Brubaker WD, Guarrera JV, Emond JC, Brown RS Jr. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience. Transplantation. 2013;95:960-965. [PMID: 23545507 DOI: 10.1097/tp.0b013e3182845f97] [Cited by in Crossref: 30] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
8 Yataco ML, Dickson RC, Bonatti H, Aranda-michel J, Mendez J, Ghabril M, Nguyen J. Dual hepatitis virus infections in liver transplant: case report and a review of the literature. Clinical Transplantation 2009;23:282-8. [DOI: 10.1111/j.1399-0012.2008.00929.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
9 López-Navidad A, Caballero F. Extended criteria for organ acceptance. Strategies for achieving organ safety and for increasing organ pool. Clin Transplant. 2003;17:308-324. [PMID: 12868987 DOI: 10.1034/j.1399-0012.2003.00119.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 74] [Article Influence: 5.4] [Reference Citation Analysis]
10 Perrillo R. Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: a survey of North American, European, and Asian-Pacific transplant programs. Liver Transpl. 2009;15:223-232. [PMID: 19177436 DOI: 10.1002/lt.21675] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis]
11 Gallegos-orozco JF, Vargas HE, Rakela J. Virologically compromised donor grafts in liver transplantation. Journal of Hepatology 2004;41:512-21. [DOI: 10.1016/j.jhep.2004.08.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
12 Loss GE, Mason AL, Nair S, Blazek J, Farr G, Guo L, Cohen AJ, Eason JD. Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors? Liver Transpl. 2003;9:1258-1264. [PMID: 14625825 DOI: 10.1016/j.lts.2003.09.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
13 Anwar N, Sherman KE. Transplanting organs from hepatitis B positive donors: Is it safe? Is it ethical? J Viral Hepat. 2018;25:1110-1115. [PMID: 29968277 DOI: 10.1111/jvh.12962] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
14 Hui CK, Yu J, Au WY, Zhang HY, Bartholomeusz A, Locarnini S, Kwong YL, Liang R, Lau GK. Sexual transmission of hepatitis B infection despite the presence of hepatitis B virus immunity in recipients of allogeneic bone marrow transplantation. J Clin Virol 2005;32:173-8. [PMID: 15653422 DOI: 10.1016/j.jcv.2004.08.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
15 Roche B, Roque-Afonso AM, Sebagh M, Delvart V, Duclos-Vallee JC, Castaing D, Samuel D. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins. Liver Transpl. 2010;16:885-894. [PMID: 20583085 DOI: 10.1002/lt.22084] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
16 Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol. 2010;52:272-279. [PMID: 20034693 DOI: 10.1016/j.jhep.2009.11.009] [Cited by in Crossref: 185] [Cited by in F6Publishing: 146] [Article Influence: 15.4] [Reference Citation Analysis]
17 Kornberg A. Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation. World J Hepatol 2015; 7(11): 1494-1508 [PMID: 26085909 DOI: 10.4254/wjh.v7.i11.1494] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Takemura N, Sugawara Y, Tamura S, Makuuchi M. Liver transplantation using hepatitis B core antibody-positive grafts: review and university of Tokyo experience. Dig Dis Sci. 2007;52:2472-2477. [PMID: 17805972 DOI: 10.1007/s10620-006-9656-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
19 Crismale JF, Ahmad J. Expanding the donor pool: Hepatitis C, hepatitis B and human immunodeficiency virus-positive donors in liver transplantation. World J Gastroenterol 2019; 25(47): 6799-6812 [PMID: 31885421 DOI: 10.3748/wjg.v25.i47.6799] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
20 Li J, Ma M, Wang X, Jiang W. Prevention and treatment of new hepatitis B after living donor liver transplantation in children. Transl Pediatr 2021;10:1610-7. [PMID: 34295775 DOI: 10.21037/tp-20-485] [Reference Citation Analysis]
21 Janssens ME, Geysen D, Broos K, De Goeyse I, Robbens J, Van Petegem F, Timmermans J, Guisez Y. Folding properties of the hepatitis B core as a carrier protein for vaccination research. Amino Acids 2010;38:1617-26. [DOI: 10.1007/s00726-009-0365-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
22 Hartwig MG, Patel V, Palmer SM, Cantu E, Appel JZ, Messier RH, Davis RD. Hepatitis B Core Antibody Positive Donors as a Safe and Effective Therapeutic Option to Increase Available Organs for Lung Transplantation: . Transplantation 2005;80:320-5. [DOI: 10.1097/01.tp.0000165858.86067.a2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
23 de Villa VH, Chen YS, Chen CL. Hepatitis B core antibody-positive grafts: recipient's risk. Transplantation. 2003;75:S49-S53. [PMID: 12589141 DOI: 10.1097/01.tp.0000047006.96782.64] [Cited by in Crossref: 51] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
24 Soejima Y, Ikegami T, Taketomi A, Yoshizumi T, Uchiyama H, Harada N, Yamashita Y, Maehara Y. Hepatitis B vaccination after living donor liver transplantation. Liver Int 2007;27:977-82. [DOI: 10.1111/j.1478-3231.2007.01521.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
25 Su WJ, Ho MC, Ni YH, Chen HL, Hu RH, Wu YM, Chang MH, Lee PH. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr. 2009;48:203-208. [PMID: 19179883 DOI: 10.1097/mpg.0b013e3181819ad4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
26 Sintusek P, Thanapirom K, Komolmit P, Poovorawan Y. Eliminating viral hepatitis in children after liver transplants: How to reach the goal by 2030. World J Gastroenterol 2022; 28(3): 290-309 [DOI: 10.3748/wjg.v28.i3.290] [Reference Citation Analysis]
27 de Villa VH, Lo CM, Chen CL. Ethics and rationale of living-donor liver transplantation in Asia. Transplantation. 2003;75:S2-S5. [PMID: 12589129 DOI: 10.1097/01.tp.0000046532.44975.57] [Cited by in Crossref: 81] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
28 Chauhan R, Lingala S, Gadiparthi C, Lahiri N, Mohanty SR, Wu J, Michalak TI, Satapathy SK. Reactivation of hepatitis B after liver transplantation: Current knowledge, molecular mechanisms and implications in management. World J Hepatol 2018; 10(3): 352-370 [PMID: 29599899 DOI: 10.4254/wjh.v10.i3.352] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
29 Cheung CK, Lo CM, Man K, Lau GK. Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis. Liver Transpl. 2010;16:1314-1323. [PMID: 21031547 DOI: 10.1002/lt.22169] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
30 Niu Y, Chen X, Feng L, You H, Ren X, Liu H, Zheng J, Shen Z, Jia J. Anti-HBc–positive/HBsAg-negative liver donors pose a higher risk of occult HBV infection but do not cause severe histological damage in liver grafts. Clinics and Research in Hepatology and Gastroenterology 2014;38:475-80. [DOI: 10.1016/j.clinre.2014.03.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
31 Scuderi V, Ceriello A, Santaniello W, Aragiusto G, Romano M, Migliaccio C, Calise F. Hepatitis B prophylaxis in hepatitis B-negative recipients transplanted with donor grafts positive for hepatitis B core antibodies. Transplant Proc. 2011;43:271-273. [PMID: 21335203 DOI: 10.1016/j.transproceed.2010.09.100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
32 Yen RD, Bonatti H, Mendez J, Aranda-michel J, Satyanarayana R, Dickson RC. Case Report of Lamivudine-Resistant Hepatitis B Virus Infection Post Liver Transplantation from a Hepatitis B Core Antibody Donor: De Novo HB Infection from an HB Core Antibody Donor . American Journal of Transplantation 2006;6:1077-83. [DOI: 10.1111/j.1600-6143.2006.01313.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
33 Pan JJ, Thosani N, Machicao VI, Fallon MB. Current use of hepatitis B immune globulin for prevention of de novo hepatitis B in recipients receiving anti-HBc-positive livers. Hepatol Int 2011;5:635-43. [PMID: 21484133 DOI: 10.1007/s12072-010-9250-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
34 Jiang L, Jiang LS, Cheng NS, Yan LN. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2009; 15(20): 2489-2499 [PMID: 19468999 DOI: 10.3748/wjg.15.2489] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
35 Fábrega E. Liver transplantation with allografts from hepatitis B core antibody-positive donors: A new approach. Liver Transplantation 2003;9:916-20. [DOI: 10.1053/jlts.2003.50190] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
36 Xie M, Rao W, Yang T, Deng Y, Zheng H, Pan C, Liu Y, Shen Z, Jia J. Occult hepatitis B virus infection predicts de novo hepatitis B infection in patients with alcoholic cirrhosis after liver transplantation. Liver Int. 2015;35:897-904. [PMID: 24750566 DOI: 10.1111/liv.12567] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
37 Wang Q, Klenerman P, Semmo N. Significance of anti-HBc alone serological status in clinical practice. The Lancet Gastroenterology & Hepatology 2017;2:123-34. [DOI: 10.1016/s2468-1253(16)30076-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 4.2] [Reference Citation Analysis]
38 Celebi Kobak A, Karasu Z, Kilic M, Ozacar T, Tekin F, Gunsar F, Ersoz G, Yuzer Y, Tokat Y. Living donor liver transplantation from hepatitis B core antibody positive donors. Transplant Proc. 2007;39:1488-1490. [PMID: 17580169 DOI: 10.1016/j.transproceed.2006.11.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
39 Saab S, Waterman B, Chi AC, Tong MJ. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. Liver Transpl. 2010;16:300-307. [PMID: 20209589 DOI: 10.1002/lt.21998] [Cited by in Crossref: 96] [Cited by in F6Publishing: 71] [Article Influence: 8.0] [Reference Citation Analysis]
40 Feng S, Lai JC. Expanded criteria donors. Clin Liver Dis 2014;18:633-49. [PMID: 25017080 DOI: 10.1016/j.cld.2014.05.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 7.1] [Reference Citation Analysis]
41 White S, Al-mukhtar A, Lodge J, Pollard S. Progress in living donor liver transplantation. Transplantation Proceedings 2004;36:2720-6. [DOI: 10.1016/j.transproceed.2004.10.030] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
42 Roque Afonso AM. Prevention of HBV reactivation from anti-HBc-positive liver grafts: searching for the consensus. Journal of Hepatology 2004;40:186-8. [DOI: 10.1016/j.jhep.2003.10.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
43 Avelino-Silva VI, D’Albuquerque LA, Bonazzi PR, Song AT, Miraglia JL, De Brito Neves A, Abdala E. Liver transplant from Anti-HBc-positive, HBsAg-negative donor into HBsAg-negative recipient: is it safe? A systematic review of the literature. Clin Transplant. 2010;24:735-746. [PMID: 20438579 DOI: 10.1111/j.1399-0012.2010.01254.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
44 Prakoso E, Strasser SI, Koorey DJ, Verran D, McCaughan GW. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. Clin Transplant. 2006;20:369-373. [PMID: 16824156 DOI: 10.1111/j.1399-0012.2006.00495.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
45 Park JB, Kwon CH, Lee KW, Choi GS, Kim DJ, Seo JM, Kim SJ, Joh JW, Lee SK. Hepatitis B virus vaccine switch program for prevention of de novo hepatitis B virus infection in pediatric patients. Transpl Int. 2008;21:346-352. [PMID: 18208419 DOI: 10.1111/j.1432-2277.2007.00618.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
46 Pillai VG, Chen CL. Living donor liver transplantation in Taiwan-challenges beyond surgery. Hepatobiliary Surg Nutr 2016;5:145-50. [PMID: 27115009 DOI: 10.3978/j.issn.2304-3881.2015.08.03] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
47 Rao W, Xie M, Yang T, Zhang JJ, Gao W, Deng YL, Zheng H, Pan C, Liu YH, Shen ZY. Risk factors for de novo hepatitis B infection in pediatric living donor liver transplantation. World J Gastroenterol 2014; 20(36): 13159-13166 [PMID: 25278711 DOI: 10.3748/wjg.v20.i36.13159] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
48 Suehiro T, Shimada M, Kishikawa K, Shimura T, Soejima Y, Yoshizumi T, Hashimoto K, Mochida Y, Maehara Y, Kuwano H. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation. Liver Int. 2005;25:1169-1174. [PMID: 16343068 DOI: 10.1111/j.1478-3231.2005.01165.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
49 Brock GN, Mostajabi F, Ferguson N, Carrubba CJ, Eng M, Buell JF, Marvin MR. Prophylaxis against de novo hepatitis B for liver transplantation utilizing hep B core (+) donors: does hepatitis B immunoglobulin provide a survival advantage? Transpl Int. 2011;24:570-581. [PMID: 21401727 DOI: 10.1111/j.1432-2277.2011.01236.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
50 Soejima Y, Shimada M, Taketomi A, Yoshizumi T, Uchiyama H, Ikegami T, Nakamuta M, Maehara Y. Successful living donor liver transplantation using a graft from a hepatitis B surface antigen-positive donor. Liver Int. 2007;27:1282-1286. [PMID: 17919241 DOI: 10.1111/j.1478-3231.2007.01528.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
51 Kim H, Choi J. Prophylaxis for Hepatitis B Core Antibody-Positive Donors after Liver Transplantation. J Korean Soc Transplant 2010;24:73. [DOI: 10.4285/jkstn.2010.24.2.73] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
52 Simpson MA, Verbesey JE, Khettry U, Morin DS, Gordon FD, Burns DL, Robson K, Pomposelli JJ, Jenkins RL, Pomfret EA. Successful Algorithm for Selective Liver Biopsy in the Right Hepatic Lobe Live Donor (RHLD). Am J Transplant 2008;8:832-8. [DOI: 10.1111/j.1600-6143.2007.02135.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
53 Miyairi I, Funaki T, Saitoh A. Immunization practices in solid organ transplant recipients. Vaccine 2016;34:1958-64. [DOI: 10.1016/j.vaccine.2016.03.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
54 Chang SH, Suh KS, Yi NJ, Choi SH, Lee HJ, Seo JK, Lee KU. Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatology. 2003;37:1329-1334. [PMID: 12774011 DOI: 10.1053/jhep.2003.50227] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
55 Skagen CL, Jou JH, Said A. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts - a systematic analysis. Clin Transplant. 2011;25:E243-E249. [PMID: 21323735 DOI: 10.1111/j.1399-0012.2011.01409.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
56 Chang MS, Olsen SK, Pichardo EM, Heese S, Stiles JB, Abdelmessih R, Verna EC, Guarrera JV, Emond JC, Brown RS. Prevention of de novo hepatitis B with adefovir dipivoxil in recipients of liver grafts from hepatitis B core antibody-positive donors. Liver Transpl. 2012;18:834-838. [PMID: 22422699 DOI: 10.1002/lt.23429] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
57 Kwon CH, Suh KS, Yi NJ, Chang SH, Cho YB, Cho JY, Lee HJ, Seo JK, Lee KU. Long-term protection against hepatitis B in pediatric liver recipients can be achieved effectively with vaccination after transplantation. Pediatr Transplant. 2006;10:479-486. [PMID: 16712607 DOI: 10.1111/j.1399-3046.2006.00540.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
58 Su WJ, Ho MC, Ni YH, Wu JF, Jeng YM, Chen HL, Wu YM, Hu RH, Chang MH, Lee PH. Clinical course of de novo hepatitis B infection after pediatric liver transplantation. Liver Transpl. 2010;16:215-221. [PMID: 20104496 DOI: 10.1002/lt.21980] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
59 Gallegos-Orozco JF, Vargas HE. Should antihepatitis B virus core positive or antihepatitis C virus core positive subjects be accepted as organ donors for liver transplantation? J Clin Gastroenterol 2007;41:66-74. [PMID: 17198068 DOI: 10.1097/01.mcg.0000225636.60404.bf] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
60 Xi ZF, Xia Q, Zhang JJ, Chen XS, Han LZ, Zhu JJ, Wang SY, Qiu DK. De novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation. J Dig Dis. 2013;14:439-445. [PMID: 23638710 DOI: 10.1111/1751-2980.12066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
61 Vizzini G, Gruttadauria S, Volpes R, D’Antoni A, Pietrosi G, Filì D, Petridis I, Pagano D, Tuzzolino F, Santonocito MM. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts. Clin Transplant. 2011;25:E77-E81. [PMID: 21039887 DOI: 10.1111/j.1399-0012.2010.01329.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]